Bachem Holding P/S 2024

Bachem Holding Aktienanalyse

What does Bachem Holding do?

The Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company was founded in 1971 in Bubendorf, Switzerland, and has been listed on the Swiss stock exchange since 1998. The company's history began with the founding of Bachem Chemie GmbH by Peter Grogg, a former chemical engineer at Ciba-Geigy. Grogg started the company with a focus on peptide synthesis, an area that was still in its infancy at the time. Over time, Bachem expanded its core business by entering into other areas such as peptide formulation, plant extract manufacturing, and nucleotide synthesis. Today, the company has around 1,400 employees worldwide and operates production and research facilities in Europe, North America, and Asia. Bachem is considered one of the largest peptide manufacturers globally and supplies customers in over 100 countries. The business model of Bachem Holding AG is heavily focused on research and development (R&D). The company invests approximately 15% of its revenue annually in R&D to maintain and expand its leading position in peptide chemistry and biochemical agents. These investments have allowed Bachem to offer a wide range of products and services that meet various customer requirements. The company operates several business segments, including peptides and biochemicals, pharmaceutical contract manufacturing and GMP manufacturing, generic drugs, research services, and products for the diagnostics market. The peptides and biochemicals segment is the core of the company and includes a wide range of peptides, amino acids, peptide libraries, peptide-drug conjugates, synthetic proteins, and bioactive peptides. Bachem also manufactures synthetic peptide kits and customized peptides for research and development. The company is also active in pharmaceutical contract manufacturing, offering customized manufacturing services for bioactive peptides, synthetic drugs, oligonucleotides, and drug-drug conjugates. Customers can benefit from synthesis development to commercial production of active substances. Bachem has also positioned itself in the generic drug market, offering a wide range of peptide-based generics such as buserelin, leuprorelin, and triptorelin. The generic drugs segment was expanded in 2015 through the acquisition of the American biotechnology company American Peptide Company. In addition to manufacturing peptides and biochemical agents, Bachem also provides research services, including peptide synthesis, peptide conjugation with drugs, analysis of protein-protein interactions, and identification of peptide libraries. The company is also active in the diagnostics market, offering a wide range of peptides and antibodies for use in diagnostic products for research and clinical applications. In summary, the Bachem Holding AG is a leading provider of peptides and biochemical agents for the pharmaceutical and biotechnological industry. The company heavily invests in research and development and offers a wide range of products and services to meet various customer requirements. Bachem Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Bachem Holding's P/S Ratio

Bachem Holding's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Bachem Holding's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Bachem Holding's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Bachem Holding’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Bachem Holding stock

What is the price-to-earnings ratio of Bachem Holding?

The price-earnings ratio of Bachem Holding is currently 9.27.

How has the price-earnings ratio of Bachem Holding changed compared to last year?

The price-to-earnings ratio of Bachem Holding has increased by -24.26% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Bachem Holding high compared to other companies?

Yes, the price-to-earnings ratio of Bachem Holding is high compared to other companies.

How does an increase in the price-earnings ratio of Bachem Holding affect the company?

An increase in the price-earnings ratio of Bachem Holding would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Bachem Holding affect the company?

A decrease in the price-earnings ratio of Bachem Holding would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Bachem Holding?

Some factors that influence the price-earnings ratio of Bachem Holding are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Bachem Holding pay?

Over the past 12 months, Bachem Holding paid a dividend of 0.38 CHF . This corresponds to a dividend yield of about 0.52 %. For the coming 12 months, Bachem Holding is expected to pay a dividend of 0.4 CHF.

What is the dividend yield of Bachem Holding?

The current dividend yield of Bachem Holding is 0.52 %.

When does Bachem Holding pay dividends?

Bachem Holding pays a quarterly dividend. This is distributed in the months of May, May, May, May.

How secure is the dividend of Bachem Holding?

Bachem Holding paid dividends every year for the past 26 years.

What is the dividend of Bachem Holding?

For the upcoming 12 months, dividends amounting to 0.4 CHF are expected. This corresponds to a dividend yield of 0.55 %.

In which sector is Bachem Holding located?

Bachem Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bachem Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bachem Holding from 4/30/2024 amounting to 0.4 CHF, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.

When did Bachem Holding pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of Bachem Holding in the year 2023?

In the year 2023, Bachem Holding distributed 0.35 CHF as dividends.

In which currency does Bachem Holding pay out the dividend?

The dividends of Bachem Holding are distributed in CHF.